• Marzieh Araghi, Rosaria GalantiMariaMDepartment of Public Health Sciences, Karolinska Institutet, Stockholm, Sweden.Centre for Epidemiology and Community Medicine, Stockholm Health Care District, Stockholm County Council, Sweden., Michael Lundberg, Anton Lager, Gunnar Engström, Lars Alfredsson, Anders Knutsson, Margareta Norberg, Malin Sund, Patrik Wennberg, Ylva Trolle Lagerros, Rino Bellocco, Nancy L Pedersen, Per-Olof Östergren, and Cecilia Magnusson.
• Department of Public Health Sciences, Karolinska Institutet, Stockholm, Sweden.
• Int. J. Cancer. 2017 Aug 15; 141 (4): 687-693.

AbstractWhile smoking is a well-established risk factor for pancreatic cancer, the effect of smokeless tobacco is less well understood. We used pooled individual data from the Swedish Collaboration on Health Effects of Snus Use to assess the association between Swedish snus use and the risk of pancreatic cancer. A total of 424,152 male participants from nine cohort studies were followed up for risk of pancreatic cancer through linkage to health registers. We used shared frailty models with random effects at the study level, to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) adjusted for confounding factors. During 9,276,054 person-years of observation, 1,447 men developed pancreatic cancer. Compared to never-snus use, current snus use was not associated with risk of pancreatic cancer (HR 0.96, 95% CI 0.83-1.11) after adjustment for smoking. Swedish snus use does not appear to be implicated in the development of pancreatic cancer in men. Tobacco smoke constituents other than nicotine or its metabolites may account for the relationship between smoking and pancreatic cancer.© 2017 UICC.

21 keywords...

hide…